Shots:
Sprint Bioscience has reported the sale of its TREX1 cancer program to Gilead Sciences
As per the Deal, Sprint Bioscience will receive $14M upfront and up to $400M in clinical, regulatory, and commercial milestones
TREX1 program has demonstrated notable potential in the pre-clinical stage
Ref: Sprint Bioscience | Image: Gilead & Sprint Bioscience | Press…
